Lakefront Biotherapeutics N.V. (LKFT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Is Lakefront Biotherapeutics N.V. stock overvalued or undervalued in 2026?
Lakefront Biotherapeutics N.V. (LKFT) trades at 3.8× earnings (P/E). No valuation verdict: it trades at 3.8 times earnings, but there is not enough data to compare it with.
Kaplio overview: Lakefront Biotherapeutics N.V.
Market cap $2B · 52 weeks $26 – $35 (8 % below the high) · P/E 3.8× · Dividend none · Next earnings November 11, 2026 · expected EPS $-0.83 · Closing price, Oct 28 · accounts published Aug 10.
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it trades at 3.8 times earnings, but there is not enough data to compare it with.
What matters in biotech: 3 of 4 pass
- Market cap / Cash 0.7×, fails.
- Cash Runway 140 meses, passes.
- Total Debt 0.0×, passes.
- R&D / Market cap 21.7 %, passes.
- Annual cash burn $3.91, info.
Against its peers (reference peers) — Lakefront Biotherapeutics N.V.: P/E 3.9×; EV/EBITDA 5.2×; ROIC 11.6 %; $2.1B. Vericel Corporation (P/E 87.8×; EV/EBITDA 56.2×; ROIC 3.8 %; $2.1B), Harmony Biosciences Holdings, Inc. (P/E 12.5×; EV/EBITDA 6.3×; ROIC 15.0 %; $2.2B), Aurinia Pharmaceuticals Inc. (P/E 7.6×; EV/EBITDA 10.6×; ROIC 21.3 %; $2.3B).
Profitability
| Return on Equity | 16.88% |
| Return on Invested Capital | 11.61% |
| Return on Assets | 14.49% |
| Gross Margin | 98.01% |
| Operating Margin | 36.43% |
| Net Margin | 46.83% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 30.48 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 8.38 |
Price Performance
| 1 month | +7.79% |
| 3 months | +16.94% |
| Year-to-date | -2.69% |
| 1 year | +2.91% |
| 3 years | -3.16% |
| 5 years | -39.95% |
| 10 years | -47.51% |
Related companies: IOVA · SLS · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of LKFT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks